Skip to main content

Table 1 Histological assessments of new bone area in the marrow of a rabbit femur

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

  Group 1 (Control) Group 2 (rh-BMP-2) Group 3 (ZOL) Group 4 (rh-BMP-2 + ZOL) p value
Haematoxylin and eosin (%, n = 9)
 3 weeks after implantation 40.0(33.1 to 42.9) 56.9(40.9 to 66.9) 11.0(8.2 to 13.4) 57.9(40.2 to 68.6) <0.001
 6 weeks after implantation 13.9(11.1 to 18.0) 13.4(9.9 to 16.9) 12.3(9.9 to 15.6) 39.0(32.0 to 47.0) <0.001
Masson’s trichrome (%, n = 9)
 3 weeks after implantation 36.5(25.4 to 40.9) 51.0(37.6 to 59.4) 13.5(10.7 to 19.9) 40.9(31.0 to 63.1) <0.001
 6 weeks after implantation 12.0(9.5 to 14.4) 11.9(6.9 to 15.5) 12.3(9.5 to 14.4) 30.0(24.3 to 30.1) <0.001
  1. Variables present percentages of new bone areas in tissues as median, minimum, and maximum. P values indicate the statistical differences between the groups. Note: β-TCP Beta-tricalcium phosphate, rh-BMP-2 Recombinant human bone morphogenetic protein-2, ZOL Zoledronate.